TaraLeeFrenklMD

Urology • Philadelphia, PA

Physician

Join to view full profile

Dr. Frenkl is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Frenkl's full profile

Already have an account?

Office
3400 Civic Center Blvd
West Pavilion, 3rd Floor
Philadelphia, PA 19104
Phone+1 215-662-2891

Fax+1 215-662-6734

Education & Training

Brown UniversityResidency, Urology, 1999 - 2003
Brown UniversityResidency, Surgery, 1998 - 1999
Duke University HospitalInternship, Transitional Year, 1996 - 1997
Rutgers Robert Wood Johnson Medical SchoolClass of 1996

Certifications & Licensure

PA State Medical License 2006 - 2024
NJ State Medical License 1992 - 2007
OH State Medical License 2003 - 2007
NC State Medical License 1997 - 1998
American Board of Urology Urology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Publications & Presentations

PubMed

240 citations
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, ...
Arjun Vasant Balar, Ashish M. Kamat, Girish S. Kulkarni, Edward Uchio, Joost L. Boormans
The Lancet. Oncology. 2021-07-01
154 citations
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelia...
Jacqueline Vuky, Arjun Vasant Balar, Daniel Castellano, Peter H. O'Donnell, Petros Grivas
Journal of Clinical Oncology. 2020-06-17
13 citations
The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States
Rachael Louise Slater, Yizhen Lai, Yichen Zhong, Haojie Li, Yang Meng
Journal of Medical Economics. 2020-06-12

Press Mentions

Bayer Expands Global Clinical Program for NUBEQA® (Darolutamide) in Prostate CancerMarch 23rd, 2023
Bayer Expands Global Clinical Program for NUBEQA® (Darolutamide) in Prostate CancerMarch 23rd, 2023
Bayer : New Data Presented at ASCO GU Confirm Survival Benefits and Favorable Safety Profile of Darolutamide Across Different Subgroups of Patients with Metastatic Hormone-Sensitive Prostate CancerFebruary 20th, 2023